- PLN124.77m
- PLN151.42m
- PLN15.76m
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects
Brief: Mabion To Conduct Due Diligence For Potential Acquisition Of Facility In U.S.
Brief: Mabion To Issue Series W And Y Shares To Convert Loans
Brief: Mabion Receives FDA Confirmation For Pre-IND Type B Meeting On MabionCD20 As Orphan Drug For ITP
Brief: Mabion Accepts New $144,900 Order From Novavax
Refile: BUZZ-Mabion shares rise after FDA submission for MabionCD20
Brief: Mabion Partner Submits FDA Documentation For MabionCD20 In ITP
Brief: Mabion Signs Deal To Sell Leak Detection, Filling And Packaging Lines
Brief: Mabion EGM To Vote On Authorising Management Board To Increase Share Capital By Up To 1.21 Mln Zlotys
Brief: Mabion Signs Annex To Extend Production Agreement With Novavax To End of 2029
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys
Brief: Mabion Signs Loan Agreement With CBC Co. For Up To EUR 3.1 Mln
Brief: Mabion Q3 Net Loss 10.8 Mln Zlotys